Bright Minds Biosciences (DRUG) News Today $34.00 +1.61 (+4.97%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$32.05 -1.95 (-5.74%) As of 01/31/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101January 26, 2025 | seekingalpha.comBright Minds Biosciences (NASDAQ:DRUG) Coverage Initiated at Piper SandlerJanuary 26, 2025 | americanbankingnews.comPiper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationJanuary 24, 2025 | msn.comBright Minds Biosciences initiated with an Overweight at Piper SandlerJanuary 23, 2025 | markets.businessinsider.comYasmeen Rahimi’s Buy Rating on Bright Minds Biosciences Driven by Promising Potential of BMB-101 for Epilepsy TreatmentJanuary 23, 2025 | markets.businessinsider.comCantor Fitzgerald Forecasts DRUG FY2025 EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will poJanuary 23, 2025 | marketbeat.comPiper Sandler sets $93 target for Bright Minds Biosciences stockJanuary 23, 2025 | msn.comBright Minds Biosciences (NASDAQ:DRUG) Earns Overweight Rating from Analysts at Piper SandlerPiper Sandler started coverage on Bright Minds Biosciences in a research report on Thursday. They set an "overweight" rating and a $93.00 price target on the stock.January 23, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationJanuary 11, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationJanuary 11, 2025 | msn.comBright Minds Biosciences initiated with a Buy at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comBright Minds Biosciences initiated with a Buy at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comBright Minds Biosciences initiated with an Overweight at Cantor FitzgeraldJanuary 10, 2025 | markets.businessinsider.comBright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Cantor FitzgeraldCantor Fitzgerald began coverage on Bright Minds Biosciences in a research note on Friday. They set an "overweight" rating on the stock.January 10, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC WainwrightHC Wainwright assumed coverage on Bright Minds Biosciences in a report on Friday. They set a "buy" rating and a $85.00 target price on the stock.January 10, 2025 | marketbeat.comTop 5 Small-cap Biotech Stocks (Updated January 2025)January 9, 2025 | msn.comTop 5 Small-cap Biotech Stocks of 2025January 8, 2025 | msn.comBright Minds Biosciences Appoints Stephen Collins As CMOJanuary 7, 2025 | markets.businessinsider.comBright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical OfficerJanuary 7, 2025 | globenewswire.comBright Minds Biosciences (NASDAQ:DRUG) Releases Earnings ResultsBright Minds Biosciences (NASDAQ:DRUG - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter.January 1, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% - Time to Sell?Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 4.3% - What's Next?December 19, 2024 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Upgraded by Baird R W to Strong-Buy RatingBaird R W upgraded shares of Bright Minds Biosciences to a "strong-buy" rating in a report on Monday.November 27, 2024 | marketbeat.comBright Minds Biosciences: Promising Pipeline and Strategic Positioning Justify Buy RatingNovember 26, 2024 | markets.businessinsider.comBaird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform RecommendationNovember 26, 2024 | msn.comBright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual MeetingNovember 22, 2024 | finance.yahoo.comBright Minds Biosciences to Present Novel Epilepsy DataNovember 22, 2024 | markets.businessinsider.comBright Minds Biosciences participates in a conference call with TruistNovember 20, 2024 | markets.businessinsider.comBright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementNovember 4, 2024 | globenewswire.comBright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market PotentialOctober 30, 2024 | seekingalpha.comShort Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 1,274.9%Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 1,170,000 shares, an increase of 1,274.9% from the September 30th total of 85,100 shares. Approximately 38.2% of the company's stock are short sold. Based on an average trading volume of 2,890,000 shares, the short-interest ratio is currently 0.4 days.October 25, 2024 | marketbeat.comSteven Cohen's Strategic Acquisition of Bright Minds Biosciences Inc SharesOctober 24, 2024 | uk.finance.yahoo.comCormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences SharesOctober 23, 2024 | finance.yahoo.comBright Minds and Firefly Neuroscience Renew CollaborationOctober 22, 2024 | markets.businessinsider.comBright Minds, Firefly Neuroscience to collaborate after BREAKTHROUGH studyOctober 22, 2024 | markets.businessinsider.comWhat's Going On With Bright Minds Biosciences Stock?October 22, 2024 | msn.comBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataOctober 21, 2024 | globenewswire.comMarketBeat Week in Review – 10/14 - 10/18 (DRUG)Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.October 19, 2024 | marketbeat.comBright Minds rebounds after $35M private placementOctober 18, 2024 | msn.comWhat's Going On With Bright Minds Biosciences Stock Friday?October 18, 2024 | msn.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Major Shareholder Cormorant Asset Management, Lp Acquires 372,591 SharesOctober 18, 2024 | insidertrades.comBright Minds Biosciences Announces US$35 Million Non-Brokered Private PlacementOctober 18, 2024 | globenewswire.comCormorant Asset Management, Lp Purchases 372,591 Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG) StockBright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) major shareholder Cormorant Asset Management, Lp acquired 372,591 shares of the stock in a transaction dated Tuesday, October 15th. The stock was acquired at an average price of $5.53 per share, for a total transaction of $2,060,428.23. Following the completion of the acquisition, the insider now directly owns 825,000 shares of the company's stock, valued at $4,562,250. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.October 17, 2024 | marketbeat.comPerceptive Advisors LLC Acquires New Stake in Bright Minds Biosciences IncOctober 16, 2024 | finance.yahoo.comBright Minds Biosciences Inc Ordinary SharesOctober 16, 2024 | morningstar.comBright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain modelsOctober 16, 2024 | globenewswire.comBright Minds Biosciences Stock Surges Almost 1,500%Bright Minds Biosciences (NASDAQ: DRUG) soared 1,445% in a single day, trading over 100 million shares without any news.October 16, 2024 | marketbeat.comBiotech stock tumbles after unexplained 1,446% gainOctober 16, 2024 | msn.comBright Minds Biosciences announces participation in upcoming scientific conferences and partnering eventsOctober 3, 2024 | globenewswire.comBright Minds Biosciences Inc Ordinary Shares DRUGOctober 3, 2024 | morningstar.comBright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thSeptember 19, 2024 | globenewswire.com Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address DRUG Media Mentions By Week DRUG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRUG News Sentiment▼0.670.69▲Average Medical News Sentiment DRUG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRUG Articles This Week▼42▲DRUG Articles Average Week Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AnaptysBio News Today Xeris Biopharma News Today Mind Medicine (MindMed) News Today Rapport Therapeutics News Today Akebia Therapeutics News Today Altimmune News Today Mineralys Therapeutics News Today Cartesian Therapeutics News Today Entrada Therapeutics News Today Alpha Teknova News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRUG) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
